POTASSIUM CHLORIDE 20MEQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ (POTASSIUM CHLORIDE 20MEQ).
Potassium is the primary intracellular cation essential for maintaining cell membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Potassium chloride supplementation corrects hypokalemia and prevents potassium depletion.
| Metabolism | Potassium is not metabolized; it is primarily excreted by the kidneys (90%) with small amounts lost in feces and sweat. |
| Excretion | Renal: >90% (primarily as potassium ions), Fecal: <10% (unabsorbed) |
| Half-life | Terminal elimination half-life is approximately 5-6 hours; clinical context: varies with renal function and potassium loads |
| Protein binding | Approximately 0-10% (minimally bound; no specific binding proteins) |
| Volume of Distribution | Approximately 0.5-1.0 L/kg (distributes primarily in extracellular fluid with gradual intracellular uptake) |
| Bioavailability | Oral: 80-100% (absorption nearly complete, minimal first-pass metabolism) |
| Onset of Action | Oral: 30-60 minutes; Intravenous: immediate (within minutes) for serum potassium increase |
| Duration of Action | Oral: effect lasts 2-4 hours for serum potassium elevation; IV: effect lasts 1-2 hours post-infusion; clinical notes: duration depends on renal function and total body potassium stores |
Oral: 20 mEq (one tablet or packet) once or twice daily, with or after meals; maximum 40 mEq per dose and 100 mEq per day. Intravenous: 10-20 mEq/hour, not exceeding 20 mEq/hour or 200 mEq/day; central line administration preferred for concentrations >40 mEq/L.
| Dosage form | INJECTABLE |
| Renal impairment | GFR ≥60 mL/min: no adjustment. GFR 30-59: use with caution, reduce dose by 25-50%. GFR <30: avoid use due to risk of hyperkalemia. |
| Liver impairment | No specific dose adjustment recommended. Monitor potassium levels closely in patients with severe hepatic impairment due to potential for acid-base disturbances. |
| Pediatric use | Neonates and infants: 1-2 mEq/kg/day divided. Children: 1-3 mEq/kg/day divided, not to exceed 1 mEq/kg/hour IV or 40 mEq/dose. Adjust based on serum potassium. |
| Geriatric use | Start at lower end of dosing range (10-20 mEq/day oral) due to age-related decline in renal function. Monitor potassium and renal function frequently. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ (POTASSIUM CHLORIDE 20MEQ).
| Breastfeeding | Potassium chloride is a normal component of breast milk. Supplementation at recommended doses does not pose risk to infant. M/P ratio not applicable as potassium is endogenous; levels in milk reflect maternal plasma levels. Use caution with high doses or potassium imbalance. |
| Teratogenic Risk | Potassium chloride is not teratogenic. Normal maternal potassium levels are essential for fetal development; both hypokalemia and hyperkalemia can cause adverse fetal outcomes. No increased risk of congenital anomalies with therapeutic use. |
■ FDA Black Box Warning
Potassium chloride injections concentrate (≥2 mEq/mL) must be diluted before use to avoid fatal hyperkalemia. Accidental administration of undiluted concentrate can cause cardiac arrest.
| Serious Effects |
["Hyperkalemia (serum potassium >5 mEq/L)","Renal failure with oliguria or anuria","Severe hemolytic reactions","Addison's disease","Acute dehydration","Heat cramps","Concurrent use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)","Solid oral forms in patients with delayed GI transit"]
| Precautions | ["Hyperkalemia risk, especially in renal impairment, rapid IV administration, or with potassium-sparing diuretics","Cardiac monitoring required during IV infusion","GI ulceration or perforation with oral solid dosage forms (use liquid or powder if GI stasis)","Use caution in patients with cardiac disease, renal impairment, or acid-base disorders","ECG changes may precede hyperkalemia"] |
Loading safety data…
| Fetal Monitoring |
| Monitor serum potassium levels, renal function, and ECG in pregnancy. Assess for signs of hyperkalemia. Fetal monitoring may include ultrasound for growth and amniotic fluid assessment if maternal potassium disturbances occur. |
| Fertility Effects | No known adverse effects on fertility. Potassium balance is important for reproductive function; severe disturbances may affect ovulation or spermatogenesis. |